Revelation Biosciences, Inc. REVB
4.01 USD +0.07 (+1.78%)
As ofNov 18, 2026, 1:02 PM EST
3.60 Day range 3.82
3.08 52-week range 40.60
- YTD
- +25.31%
- 1 year
- +16.57%
News
benzinga.com Revelation Biosciences Plans Accelerate Development Of Its Therapeutic Candidate Gemini; New Streamlined Phase 2a Study In Acute Kidney Injury To Deliver Topline Data In 2027 At Nearly 90% Lower Costs The strategy includes advancing a streamlined Phase 2a clinical study in patients with stage 2 or 3 acute kidney injury (AKI) to generate safety and efficacy data more rapidly and at substantially…
businesswire.com Revelation Biosciences Announces Accelerated Gemini Development Plan and Strategic Partnership Initiatives SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative therapies designed…benzinga.com Revelation Biosciences Q3 EPS $(5.92) Beats $(6.16) Estimate Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(5.92) per share which beat the analyst consensus estimate of $(6.16) by 3.9 percent. This is a 88.04 percent increase over losses…
